SAN RAMON, Calif., Oct. 12, 2021 /PRNewswire/ -- CooperVision, a
global leader in myopia management, today announced a new U.S.
education initiative called "Take Control: Myopia & You" to
increase awareness of the disease and encourage parents to schedule
eye exams for their young children. Childhood myopia has been
increasing in prevalence and severity in recent
decades,1 a trend which may have been exacerbated
by increased time spent on screens and other "near work" indoors
during the ongoing COVID-19 pandemic.2
CooperVision's new U.S. parent education initiative will increase
awareness of myopia progression and MiSight® 1 day.
CooperVision's nationwide education campaign will build upon the
Brilliant Futures™ Myopia Management Program featuring
MiSight® 1 day contact lenses, which are specifically
designed for myopia control and are FDA* approved to slow the
progression of myopia in children aged 8-12 at the initiation of
treatment.†3
Clinical evidence underscores the efficacy of
MiSight® 1 day contact lenses. Data shows that children
using the lenses experienced a 59% reduced rate of myopia
progression and a 52% reduced rate of axial elongation over three
years, on average†3. Also, children wearing
MiSight® 1 day contact lenses progressed less than
-1.00D over six years, on
average.‡4
"Thousands of U.S. eye care professionals have already chosen to
act today to change tomorrow, making MiSight® 1 day
available in all 50 states plus Puerto
Rico," said Jerry Warner,
Executive Vice President, Americas and Global Commercial Functions
for CooperVision. "Now we're encouraging additional parents to act
by learning more and having these conversations with their eye
doctor. They can make a significant difference in their children's
eye health, and we're there to help along the way."
Nine-year-old Alan Kim will serve
as a primary spokesperson. The child actor is known for his role in
Minari (2021), for which he was nominated for a BAFTA Award
for Best Actor in a Supporting Role and won a Critics Choice Movie
Award for Best Young Performer. Kim has myopia and will share his
MiSight® 1 day experience, demonstrating how he can wear
contact lenses successfully at his age and enjoy the benefits of
increased confidence and freedom in everyday activities.
Actress and singer, Madison
Reyes, 17, will also support the campaign by sharing her
experience with myopia and the lifestyle benefits of contact lens
wear.5 Reyes is most known for her role in the
Netflix musical series Julie and the
Phantoms (2020), for which she received an MTV Movie
and TV Award for Best Musical Moment, an Imagen Foundation Award
for Best Young Actor, and a nomination for a Daytime Emmy
Award.
The campaign spokespeople, together with the clinical evidence
of MiSight® 1 day's efficacy, address top considerations
parents have expressed in CooperVision research.6 Focus
group participants have identified knowing the facts and
confirmation that their age-appropriate children can handle contact
lenses as key to their decision when an eye care professional
prescribes the Brilliant Futures™ Myopia Management Program.
In addition to celebrity spokespeople, the omnichannel "Take
Control: Myopia & You" campaign will feature notable eye care
professionals. Content will live across owned channels and
established parenting platforms, creating an information hub where
parents can seek more information and get their questions
answered.
To learn more, visit
https://coopervision.com/practitioner/myopia-management.
*Indications for use: MiSight® 1 day
(omafilcon A) soft (hydrophilic) contact lenses for daily wear are
indicated for the correction of myopic ametropia and for slowing
the progression of myopia in children with non-diseased eyes, who
at the initiation of treatment are 8-12 years of age and have a
refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤
0.75 diopters of astigmatism. The lens is to be discarded after
each removal.
†Compared to a single vision 1 day lens over a 3-year
period.
‡Fitted at 8-12 years of age at initiation of
treatment.
About CooperVision
CooperVision, a division of
CooperCompanies (NYSE:COO), is one of the world's leading
manufacturers of contact lenses. The company produces a full array
of daily disposable, two-week and monthly soft contact lenses that
feature advanced materials and optics, and premium rigid gas
permeable lenses for orthokeratology and scleral designs.
CooperVision has a strong heritage of addressing the toughest
vision challenges such as astigmatism, presbyopia, childhood
myopia, and highly irregular corneas; and offers the most complete
portfolio of spherical, toric and multifocal products available.
Through a combination of innovative products and focused
practitioner support, the company brings a refreshing perspective
to the marketplace, creating real advantages for customers and
wearers. For more information, visit www.coopervision.com.
About CooperCompanies
CooperCompanies ("Cooper") is a
global medical device company publicly traded on the NYSE
(NYSE:COO). Cooper operates through two business units,
CooperVision and CooperSurgical. CooperVision brings a refreshing
perspective on vision care with a commitment to developing a wide
range of high-quality products for contact lens wearers and
providing focused practitioner support. CooperSurgical is committed
to advancing the health of women, babies and families with its
diversified portfolio of products and services focusing on medical
devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of
more than 12,000 with products sold in over 100 countries. For more
information, please visit www.coopercos.com.
Media Contact
Hannah
Barry, McDougall Communications
hannah@mcdougallpr.com or +1-585-645-8985
1 Holden et al, - Global Prevalence of myopia and
high myopia and temporal trends from 2000 through 2050.
Ophthalmology 2016. 123(5):1036 -1042
2 Wang J, Li Y, Musch DC, Wei N, Qi X, Ding G, Li X,
Li J, Song L, Zhang Y, Ning Y, Zeng X, Hua N, Li S, Qian X.
Progression of Myopia in School-Aged Children After COVID-19 Home
Confinement. JAMA Ophthalmol. 2021 Jan 14:e206239. doi:
10.1001/jamaophthalmol.2020.6239. Epub ahead of print. PMID:
33443542; PMCID: PMC7809617.
3 Chamberlain P, et al. A 3-year randomized clinical
trial of MiSight® lenses for myopia control. Optom Vis
Sci. 2019; 96(8):556 -67.
4 Chamberlain P, Arumugam B, Jones D et al. Myopia
Progression in Children wearing Dual-Focus Contact Lenses: 6-year
findings. Optom Vis Sci 2020;97(E-abstract): 200038.
5 Rah MJ, et al. Vision specific quality of life of
pediatric contact lens wearers. Optom Vis Sci2010;87(8):560-6 .
6 CVI data on file 2021. Brilliant Futures™
Myopia Management Program Parent Experience Research Report.
Decision Analyst, June 2021 .
View original content to download
multimedia:https://www.prnewswire.com/news-releases/coopervision-launches-new-myopia-education-campaign-for-us-parents-301397493.html
SOURCE CooperVision